Back to Search
Start Over
Towards depersonalized abacavir therapy
- Source :
- AIDS. 29:2385-2395
- Publication Year :
- 2015
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2015.
-
Abstract
- OBJECTIVE Exposure to abacavir is associated with T-cell-mediated hypersensitivity reactions in individuals carrying human leukocyte antigen (HLA)-B57 : 01. To activate T cells, abacavir interacts directly with endogenous HLA-B57 : 01 and HLA-B57 : 01 expressed on the surface of antigen presenting cells. We have investigated whether chemical modification of abacavir can produce a molecule with antiviral activity that does not bind to HLA-B57 : 01 and activate T cells. DESIGN An interdisciplinary laboratory study using samples from human donors expressing HLA-B57 : 01. Researchers were blinded to the analogue structures and modelling data. METHODS Sixteen 6-amino substituted abacavir analogues were synthesized. Computational docking studies were completed to predict capacity for analogue binding within HLA-B57 : 01. Abacavir-responsive CD8 clones were generated to study the association between HLA-B57 : 01 analogue binding and T-cell activation. Antiviral activity and the direct inhibitory effect of analogues on proliferation were assessed. RESULTS Major histocompatibility complex class I-restricted CD8 clones proliferated and secreted IFNγ following abacavir binding to surface and endogenous HLA-B57 : 01. Several analogues retained antiviral activity and showed no overt inhibitory effect on proliferation, but displayed highly divergent antigen-driven T-cell responses. For example, abacavir and N-propyl abacavir were equally potent at activating clones, whereas the closely related analogues N-isopropyl and N-methyl isopropyl abacavir were devoid of T-cell activity. Docking abacavir analogues to HLA-B57 : 01 revealed a quantitative relationship between drug-protein binding and the T-cell response. CONCLUSION These studies demonstrate that the unwanted T-cell activity of abacavir can be eliminated whilst maintaining the favourable antiviral profile. The in-silico model provides a tool to aid the design of safer antiviral agents that may not require a personalized medicines approach to therapy.
- Subjects :
- Anti-HIV Agents
Immunology
HIV Infections
Microbial Sensitivity Tests
Human leukocyte antigen
CD8-Positive T-Lymphocytes
Biology
Pharmacology
Major histocompatibility complex
Drug Hypersensitivity
immune system diseases
Abacavir
medicine
Humans
Immunology and Allergy
Cytotoxic T cell
Antigen-presenting cell
virus diseases
Virology
Dideoxynucleosides
HLA-B
Molecular Docking Simulation
Infectious Diseases
HLA-B Antigens
Docking (molecular)
biology.protein
CD8
Protein Binding
medicine.drug
Subjects
Details
- ISSN :
- 02699370
- Volume :
- 29
- Database :
- OpenAIRE
- Journal :
- AIDS
- Accession number :
- edsair.doi.dedup.....fe2481479e392b96f2f1301df608ef60
- Full Text :
- https://doi.org/10.1097/qad.0000000000000867